Bortezomib resistance in multiple myeloma is associated with increased serine synthesis

Background The proteasome inhibitor bortezomib (BTZ) is successfully applied in the treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of resistance. Metabolic alterations play an important role in cancer development and aid in the cellular adaptation to phar...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cancer & metabolism Ročník 5; číslo 1; s. 7 - 12
Hlavní autori:	Zaal, Esther A., Wu, Wei, Jansen, Gerrit, Zweegman, Sonja, Cloos, Jacqueline, Berkers, Celia R.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 29.08.2017 BioMed Central Ltd Springer Nature B.V BMC
Predmet:	Apoptosis Biomedical and Life Sciences Biomedicine Biosynthesis Bortezomib Breast cancer Cancer Research Cancer therapies Carbon Cell Biology Cell growth Dehydrogenases Drug resistance Drug therapy Experiments Imaging Inhibitor drugs Mass spectrometry Melanoma Metabolic Diseases Metabolism Metabolomics Multiple myeloma Mutation Oncology Patient outcomes Penicillin PHGDH Proteins Radiology Scientific imaging Targeted cancer therapy Testing PHGDH Bortezomib Metabolism Drug resistance Multiple myeloma
ISSN:	2049-3002, 2049-3002
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!